Timetable

Thursday, November 21, 2013
18:00-19:30 Opening Session
19:30-20:30 Welcome reception



Friday, November 22, 2013
Hall A
Hall B
Hall C
08:30-10:00 Session A1Does the FRAX index really reflect society, and therefore, useful in the treatment of osteoporosis (OP)? Session B1New therapeutic directions in osteoarthritis (OA)
Partially supported by an unrestricted grant from IBSA Institut Biochimique SA 

 

10:00-10:30 Coffee break & poster viewing
10:30-12:00 Session A2New insights in pathogenesis of rheumatoid arthritis (RA)
Session B2Integration of herbal medicine in joint pain management: Utopia or reality?
Supported by an unrestricted grant from Tilman S.A.

 

12:00-12:50 Lunch break
12:50-14:20 Session A3Bisphosphonates: How long is long enough? The concept of a drug holiday Session B3Pain and physical activity: Friend or Foe?

Session FC1

Free Communications: Muscles

14:20-14:40 Poster viewing
14:40-16:10 Session A4The future of osteoporosis treatment
Endorsed and organized by the European Menopause and Andropause Society (EMAS) 
Session B4What is the real risk factor for OA: To be a woman or to develop an estrogen deficiency?

Session FC2

Free Communications: Rheumatoid arthritis and pain

16:10-16:30 Coffee break & poster viewing
16:30-18:00 Session A5 From early to late post menopausal osteoporosis Session B5Exercise and orthoses as treatment of OA: Can we expect a structural effect?

Session C1

Applying omics techniques to discover new OA biomarkers
This session is endorsed and organized by the D-Board F7 consortium for new OA



Saturday, November 23, 2013
Hall A
Hall B
Hall C
08:30-10:00 Session A6Sarcopenia: Impact of nutrition on muscle mass, strength and performance in older adults Session B6Biomarkers to predict OA progression
Supported by an unrestricted grant from Artialis

 

10:00-10:30 Coffee break & poster viewing
10:30-12:00 Session A7Latest updates and new treatments in BMJD in 2013 Session B7Osteoarthritis and the future of therapy: Should we invest in basic research or in clinical care programs?

Session FC3

Free Communications:
Osteoporosis
12:00-12:50 Lunch break
12:50-14:20 Session A8Cartilage homeostasis and degeneration Session B8Is there a better treatment than placebo for OA?

Session FC4

Free Communications:
Osteoporosis and osteoarthritis
14:20-14:40 Poster viewing
14:40-16:10 Session A9Innovations in surgery to repair musculoskeletal tissue

Supported by an unrestricted grant from Synolyne S.A.

Session B9New molecules in development

Session FC5

Free Communications:
Osteoarthritis
16:10-16:30 Coffee break & poster viewing
16:30-18:00 Session A10Managing bones in patients with cancer and liver diseases Session B10Strategies in early RA and sponndyloarthropathies

Session FC6

Free Communications:
Joint Disease


Sunday, November 24, 2013
Hall A
Hall B
08:30-10:00 Session A11Different ways to evaluate and control RA Session B11Controversial issues in Osteoporosis and Osteoarthritis
Endorsed and organized by the Portuguese Society of Osteoporosis and Other Metabolic Bone Diseases (SPODOM)

10:00 - 10:30 Coffee break
10:30-12:00 Session A12Hydrolysate collagen to treat OA: What's the evidence?
Session B12Surgery of OA joints


 

Keep me updated

KeepMeUpdated2